Emmaus Life Sciences (Emmaus Life Sciences) EBIT : $2.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences EBIT?

Emmaus Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $2.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $2.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Emmaus Life Sciences's annualized ROC % for the quarter that ended in Sep. 2023 was 0.07%. Emmaus Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 308.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Emmaus Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 5.16%.

Emmaus Life Sciences EBIT Historical Data

The historical data trend for Emmaus Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences EBIT Chart

Emmaus Life Sciences Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-10.25

-27.05

6.96

-12.82

-5.55

Emmaus Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															1.09	1.69	-1.98	0.28	2.01

Competitive Comparison of Emmaus Life Sciences's EBIT

For the Biotechnology subindustry, Emmaus Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's EV-to-EBIT falls into.

Emmaus Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.00 Mil.

Emmaus Life Sciences (OTCPK:EMMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Emmaus Life Sciences's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	0.096 * ( 1 - 36.19% )	/	( (87.632	+	83.672)	/ 2 )
=	0.0612576	/	85.652
=	0.07 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	50.288	-	14.356	-	( 1.361	-	max(0, 61.547	-	9.847	+	1.361	))
=	87.632

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	47.453	-	15.441	-	( 1.505	-	max(0, 60.917	-	9.257	+	1.505	))
=	83.672

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Emmaus Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	8.056	/	( ( (2.653 + max(-21.819, 0))	+	(2.57 + max(-23.455, 0)) )	/	2 )
=	8.056	/	( ( 2.653	+	2.57 )	/	2 )
=	8.056	/	2.6115
=	308.48 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5.573	+	1.814	+	1.099)	-	(14.356	+	10.844	+	5.105)
=	-21.819

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.587	+	1.65	+	1.515)	-	(15.441	+	10.844	+	4.922)
=	-23.455

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Emmaus Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	2	/	38.766
	=	5.16 %

Emmaus Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website

https://www.emmausmedical.com

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Executives

Seah H. Lim	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee	director, officer: Vice Chairman & COO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara	director, 10 percent owner, officer: Chairman and CEO	20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi	director	1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark	officer: SVP, Clinical Development	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich	officer: CIO & SVP	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood	director	956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii	officer: Chief Financial Officer	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato	director	3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran	officer: Chief Administrative Officer	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey	director	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki	officer: Sr. VP Finance	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501